Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C

NCT03001076 is registered in ClinicalTrials.gov with Esperion Therapeutics, Inc. as lead sponsor.

NCT NCT03001076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03001076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C
Lead sponsor
Esperion Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 29, 2016
Completion date
February 12, 2018
Enrollment
269 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, hypercholesterolemia, statin adverse reaction